Evolution of Technology
- 2006: ONsync Dynamic
Electrochemistry technology approved - 1990s: Static Electrochemistry-Coulometry technology approved
- 1980s: Static Electrochemistry-Amperometry technology approved
- 1980s
- 1990s
- 2000
- 2006
- 2008
- 2010
Download a Clinical Summary Whitepaper »
Superior Technology

ONsync Dynamic Electrochemistry technology automatically adjusts for common sources of error that make blood glucose measurements inaccurate.
While most meters still use static electrochemistry to calculate blood glucose levels, patented ONsync employs Dynamic Electrochemistry® – the latest in blood glucose testing technology– to capture much richer information than other blood glucose testing meters.

Traditional static electrochemistry may be inaccurate due to the many variations in the blood sample.
The system is so complex, more than 42 patents protect its exclusive intelligence. Furthermore, meters powered by ONsync are the first blood glucose meters to directly connect to iPhone®, iPod touch® and iPad®.
And the advanced datamanagement features of ONsync-powered meters include 14-, 30- and 90-day averages and graphs of test results that can easily be viewed and downloaded to a computer.
Incredible Accuracy

FDA standards require +/- 20% accuracy 95% of the time. Meters powered by ONsync were within +/-10% 93% of the time.**
Using one of the smallest blood sample sizes required, meters and strips powered by ONsync automatically adjust for common sources of error to improve accuracy. Common sources of error include: temperature and altitude changes, chemical interferences from food and beverages, blood sample variations and manufacturing differences. And accuracy is critical; In the short-term, when patients are deciding on insulin therapy requirements, and in the long-term, to ensure a long, high quality of life, free from diabetes complications.*
Interfering Substances
Triglyceride500 mg/dLNo Significant Effect
Interferent | Concentration | Effect |
Ascorbic Acid | 2 mg/dL | No Significant Effect |
Acetaminophen | 10 mg/dL | No Significant Effect |
Bilirubin | 15 mg/dL | No Significant Effect |
Caffeine | 6 mg/dL | No Significant Effect |
Cholesterol | 600 mg/dL | No Significant Effect |
Fructose | 18 mg/dL | No Significant Effect |
Galactose | 15 mg/dL | No Significant Effect |
Ibuprofen | 50 mg/dL | No Significant Effect |
Lactose | 10 mg/dL | No Significant Effect |
Lipoic Acid | 2 mg/dL | No Significant Effect |
Maltose | 20 mg/dL | No Significant Effect |
Methyl-DOPA | 1.5 mg/dL | No Significant Effect |
Salicylate | 60 mg/dL | No Significant Effect |
Sucrose | 20 mg/dL | No Significant Effect |
Tolazamide | 5 mg/dL | No Significant Effect |
Uric Acid | 9 mg/dL | No Significant Effect |
** The FDA requires that glucose meters be within +/- 20% of a lab standard 95% of the time. In a recent clinical study, ONsync-enabled meters provided results within +/-10% of a lab standard 93% of the time. Based on an ISO 15197 system accuracy study: Type 1 & 2 participants, YSI reference.